Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320185 | 0.85 | AOC3 (0.46) | AOC3SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL6318414 | 0.84 | HRH3 (0.50) | AOC3SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL6320706 | 0.80 | KDM4E (0.54) | AOC3SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL25101015 | 0.79 | TAAR1 (0.54) | AOC3SMN1; SMN2KDM4ESLC6A2SLC6A4 | |
| SCHEMBL16327150 | 0.79 | AOC3 (0.48) | AOC3SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6320573 | 0.79 | TAAR1 (0.54) | AOC3SMN1; SMN2KDM4ESLC6A2SLC6A4 | |
| SCHEMBL9196325 | 0.78 | AOC3 (0.41) | AOC3SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1239178 | 0.78 | AOC3 (0.47) | AOC3SMN1; SMN2MEN1KMT2ASLC6A2 | |
| SCHEMBL6281264 | 0.78 | AOC3 (0.72) | AOC3SMN1; SMN2MEN1KMT2ASLC6A2 | |
| SCHEMBL1205131 | 0.78 | AOC3 (0.72) | AOC3KDM4EMEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | AOC3 4410/4885SMN1; SMN2 947/4885KDM4E 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.